idea-003 · RUO · wrapped
Read this before anything else on the page. A low count here is usually a
statement about this repo's tooling rather than about the idea — a
unconfirmed reimbursement claim most often means the CMS cache file
is absent and nothing was searched, which is not evidence that a code
does not exist.
The packet a human reads. See docs/wrap-spec.md. This section says nothing about whether the idea is good — it says the file is finished enough to be read, and names what to do next. Filling it in advances no candidate and approves nothing.
The one-paragraph version. A set of reference samples sold to the laboratories that run blood tests for leftover cancer after surgery. Those tests look for a handful of tumour DNA fragments among millions of normal ones, and a lab has to prove how faint a signal it can reliably detect before it can offer the test clinically. Today labs mostly make their own practice samples, or buy commercial ones built from cell-line DNA in an artificial liquid. This product is made from pooled human donor plasma instead, so it behaves like a real patient sample, with known quantities of tumour DNA spiked in at levels far fainter than anything currently sold. It is sold as a laboratory research product, not a medical device, and it has no insurance code of its own — the labs pay for it out of their own budgets.
What would have to be true, quoted from each deck's load-bearing condition:
Cheapest next test: Restore the three CMS cache files named in this file's own gap analysis — data/hcpcs_payment_rates.csv, data/medicare_procedure_volumes.csv and data/medicare_coverage_policies.csv — and re-run payment 0340U, procedures 0340U and coverage 0340U. Three claims resolve on one Verifier pass with no new research. Selected from the Reimbursement and TAM rows of the Scores table, where all three are recorded as blocked on "No local cache at ..." rather than on a negative result; this is a selection from that gap analysis, not a new judgement, and not a view about the idea.
Where the evidence actually stands. 5 of 46 claims verified, 41 unconfirmed, none refuted. All 9 factors carry a score in the Stage 2 triage table and all 4 core factors do; read the Verified Composite for the narrower verified-context count.
The single most important thing for a Stage 6 reader to know is that this candidate's cheapest next test was already possible and was never run. The CMS caches those three claims need were populated on 2026-08-30 — idea-001 in this same portfolio records all five files present and re-verified nine of its claims against them that day. idea-003 was not re-run. Its reimbursement and TAM position is therefore not blocked on an unavailable file or an unknown fact; it is blocked on a pass nobody scheduled. (The caches are gitignored and do not travel between sessions, so restoring them is the first step.)
Two things a reader should not misread. First, the five verified claims are unusually many for this repo and they are all regulatory or definitional [claim 4: verified], [claim 5: verified], [claim 6: verified], [claim 7: verified], [claim 22: verified]. A high verified count is a well-mapped position, not a strong one — and two of those five point at different regulations for the same material, which is why the regulatory question is the first to settle rather than a settled one. Second, thirteen claims were added by the research lane since 2026-08-24 and not one of them moved a tag, because vendor specification pages, press releases and earnings calls have no connector in this repo, and a literature scan can locate a paper but never appraise it.
That new evidence still changed the picture materially in both directions, and both belong in front of a human. In the candidate's favour: the two incumbent product lines that could be read both stop at 0.1% VAF, in a "plasma like matrix" [claim 45: unconfirmed] and in synthetic plasma matrix from fragmented cell-line DNA [claim 46: unconfirmed] — neither reaching the sub-0.01% range on native donor plasma this product is built around, so the competitive gap it claims is now documented rather than asserted. Against it: a multi-manufacturer study across eight NGS platforms found reproducibility degrading as allele fraction fell, with poor repetition below 0.5% [claim 39: unconfirmed], and the field's formal proficiency-testing programme operates at 0.5%-2.5% [claim 40: unconfirmed]. The panel's target range begins 50 to 500 times below where the discipline has demonstrated it can work reproducibly. That is the same wall the file's own Poisson claim describes [claim 16: unconfirmed], now with an empirical measurement beside it — and it is simultaneously the reason the gap exists and the reason it may not be fillable.
| Intended use | For Research Use Only, not for use in diagnostic procedures — intended for use by molecular laboratories to characterize the limit of detection, specificity, and inter-run precision of tumor-informed circulating tumor DNA minimal residual disease assays during assay development and ongoing performance monitoring. |
|---|---|
| Mechanism | Contrived plasma reference material built on pooled human donor plasma retaining native cell-free DNA fragmentomic profile, spiked with characterized variant-bearing fragments at defined ultra-low allele fractions (roughly 0.001%-0.5% VAF), each level orthogonally quantified by digital PCR with a published uncertainty budget, supplied as a multi-level panel plus a daily-use single-level control |
| Device class | # Three live routes, carried rather than resolved (backlog 3.8).; RUO — 21 CFR 809.10(c) — launch designation. NOTE: 809.10(c) exempts a shipment from the; IVD labeling requirements of (a)/(b) and from a part 861 standard. It says nothing about; premarket review, so it does not by itself place this product outside it (see claim 1).; Class I — 21 CFR 862.1660 — repositioning route as clinical QC material. 510(k)-exempt,; but 862.9(c)(1) withdraws the exemption for devices intended for the diagnosis,; monitoring or screening of neoplastic diseases. Verified to exist, not verified to apply.; Class II — 21 CFR 866.5910 — the route FDA's own NZB product code points at. 866.5910(b); is 510(k)-exempt on its face and the section is scoped to cystic fibrosis nucleic acid; assays, so it does not establish where a cfDNA MRD panel lands. 866.9(c)(1) is word-for-; word identical to 862.9(c)(1), and 866.9(a) adds a different-intended-use limb. |
| Predicate or analog | LGC Clinical Diagnostics Seraseq ctDNA reference materials; Revvity/Horizon Discovery HDx cfDNA reference standards; Twist Bioscience cfDNA reference standards. No FDA-cleared analog identified for MRD-range (sub-0.01% VAF) commutable material |
| Launch jurisdiction | US |
| Target | RUO |
| Factor | Score | What would settle it |
|---|---|---|
| Regulatory pathway | 3 | Human attaches eCFR permalinks or PDFs for 21 CFR 809.10(c), 862.1660, and the 862.9 exemption limitations, read in full; plus FDA guidance "Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use…the rest of this gap analysisOnly" retrieved from fda.gov.python3 -m connectors classification --device-name "quality control material" and --product-code <code> can resolve claim 6, but only for the clinical QC SKU. No connector can ever verify the RUO half: "no premarket review required" is a negative about an unregulated product, and openFDA holds no record of a non-device. |
| Reimbursement pathway | n/a — not scored | Nothing settles this factor, because it does not apply to an RUO consumable. To settle the indirect dependency: python3 -m connectors cpt 0340U returns unverifiable by design and permanently — CPT descriptors are AMA-licensed, so…the rest of this gap analysisa human must attach the AMA PLA descriptor for 0340U. MolDX article A58456 must be opened by a human in the CMS Medicare Coverage Database;python3 -m connectors coverage keys on a HCPCS code, not on a MolDX article ID. |
| TAM | 2 | python3 -m connectors procedures 0340U --expect-volume 100000 for the volume floor (may return unconfirmed if the cached CMS utilization file does not carry PLA codes — that is a real answer, not a tooling failure). `python3 -m…the rest of this gap analysisconnectors payment 0340U --min-expected 3500 against the CLFS/ADLT file for component 1 at current-year rates. python3 -m connectors market "QC spend as 0.5-1.5% of lab test revenue" returns unverifiable` by design — component 3 needs a human-attached licensed lab-economics report. Component 4 needs a human-attached enumeration of US labs offering or developing tumor-informed MRD (MolDX-registered lab list plus CAP and NY CLEP directories). Claim 15 needs the ACLA v. FDA opinion, court, and docket number attached by a human. |
| FTO / IP | 3 | python3 -m connectors patent US<number> once real numbers exist — note this checks a named patent family's status and cannot perform a freedom-to-operate search. Real resolution requires a human-commissioned patent landscape covering…the rest of this gap analysiscontrived cfDNA reference material composition, native fragmentomic profile preservation, and ultra-low-VAF variant spiking, screening assignees LGC, Revvity/Horizon, Twist, Natera, Guardant, and Illumina/Grail, attached as a search report. |
| Moat / defensibility | 2 | No connector settles this. Needs a human-attached reading of ISO 17034 and the CAP Molecular Pathology checklist (MOL series) establishing whether third-party traceable reference material is required, merely accepted, or irrelevant to…the rest of this gap analysisa validation packet — that distinction is the entire moat. Claim 21 is adoption-class:python3 -m connectors adoption "<preference claim>" returns unverifiable by design, so it needs primary customer discovery with named MRD laboratory directors, attached as interview notes. |
| Mechanism & clinical risk | 2 | No connector can settle this — it is a bench question. Needs an internal dPCR replicate series establishing achievable CV and a defensible uncertainty budget at each panel level with DNA input mass stated, attached as bench data. `python3…the rest of this gap analysis-m connectors literature "circulating tumor DNA reference material limit of detection commutability"` can surface published Poisson-limit and LoD analyses that bound the answer before any wet-lab spend. This is the first item any Stage 7 diligence package should fund. |
| Capital intensity & time-to-revenue | 4 | No connector applies; this is an internal estimate, not an external fact, and it stays unverified until a human attaches a bottom-up build plan: digital PCR platform quote, consented/IRB donor plasma sourcing contract with per-liter…the rest of this gap analysiscost, ISO 17034 accreditation quote and calendar from an accreditation body (e.g. A2LA), and a headcount and facility plan through first shipment. |
| Competitive intensity | 2 | No FDA connector applies: RUO products are never cleared, so clearances and recalls will be silent by construction — that silence is not evidence of an empty field and must not be read as such. Needs a human to pull current catalog…the rest of this gap analysisspec sheets and certificates of analysis for Seraseq ctDNA, Revvity/Horizon HDx cfDNA, and Twist cfDNA reference standards, recording the lowest characterized VAF level and matrix type per SKU.python3 -m connectors literature "ctDNA reference material commutable low allele fraction" for independent published characterizations of the existing materials. |
| Strategic fit & portfolio balance | 3 | A human-supplied portfolio thesis or capital-allocation document stating the intended mix of hero bets versus cash-generative spokes and the current holdings to balance against. No connector; this factor is Stage 6 territory by design and…the rest of this gap analysisshould be expected to remain unresolved through Stage 4. |
All six wrap criteria are met.
Domain dossier: ctdna-mrd-assay-validation
Source file: knowledge-base/candidates/idea-003.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.